The healthcare system needs stronger IP protection
Declan Hamill, chief of staff and vice president (legal affairs) for Rx&D tells James Nurton why the innovative life sciences industry has concerns about the lack of patent term restoration, utility standards and access to medicines
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: